Last reviewed · How we verify

Epilim — Competitive Intelligence Brief

Epilim (sodium valproate) competitive landscape: 0 comparators, recent regulatory actions, upcoming PDUFA, patent timeline. Area: Neuroscience.

marketed Alcohol dehydrogenase [NADP(+)], Histone deacetylase 1, Histone deacetylase 2 Neuroscience Live · refreshed every 30 min

Target snapshot

Epilim (sodium valproate) — Sanofi.

Comparator set

Auto-detected by same drug class / molecular target / therapeutic area, ranked by phase + recency. Override with ?vs=slug1,slug2,….

DrugGenericSponsorPhaseClassTargetApproval / PDUFA
Epilim TARGET sodium valproate Sanofi marketed Alcohol dehydrogenase [NADP(+)], Histone deacetylase 1, Histone deacetylase 2

Recent regulatory actions (last 90 days)

No regulatory actions in the last 90 days for this set.

Upcoming PDUFA dates (next 180 days)

No PDUFA dates in the next 180 days for this set.

Patent timeline (forward window)

No upcoming patent expiries for this set.

Sponsor landscape

No sponsor landscape data.

Subscribe to ongoing alerts

Push every new event for this competitive set into your RSS reader, IFTTT/Zapier workflow, or email digest:

Cite this brief

Drug Landscape (2026). Epilim — Competitive Intelligence Brief. https://druglandscape.com/ci/sodium valproate. Accessed 2026-06-10.

Build your own brief

Pick any drug + add comparators:

Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing